MedTrace Logo

A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19

NCT04555213 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-08-26

No results posted yet for this study

Summary

Phase Ib, open-label, multicenter, study of NOX66, given rectally to hospitalized patients with moderate systemic illness due to COVID-19 infection at high risk of developing severe sepsis / septic shock.

Conditions

  • Covid19

Interventions

DRUG

NOX66

NOX66 Suppository

Sponsors & Collaborators

  • Noxopharm Limited

    lead INDUSTRY

Principal Investigators

  • Gisela Mautner, MD, PhD · Noxopharm Limited

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-30
Primary Completion
2021-08-10
Completion
2021-08-10

Countries

  • Moldova

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04555213 on ClinicalTrials.gov